Skip to Main Content

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and refreshing, because that oh-so-familiar routine of meetings, deadlines, calls, and the like has, of course, returned. You knew this would happen, yes? After all, the world keeps spinning no matter how hard we try to slow things down a bit. So what else is there to do but reach for a cup of stimulation — our choice is whiskey-flavored Jack Daniels — and get started on the journey? Hope yours goes well and, as always, do keep in touch …

Pfizer (PFE) plans to acquire Array Biopharma (ARRY) for $11.4 billion in cash, which is known not only for developing its own medicines but as being a top choice among biotechnology firms that need to synthesize new drugs, STAT writes. The deal gives Pfizer access to a pair of drugs that are approved for treating metastatic melanoma. The combined therapy is currently being tested in more than 30 clinical trials for other tumor-related diseases, such as metastatic colorectal cancer.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!